CLDN6 and cancer: CLDN6 is studied to be used for emerging immunotherapies to treat cancers including monoclonal antibodies, bispecific antibodies (BsAbs), antibody–drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapy (Figure 2).